Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Motion Sickness

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Motion Sickness. Displaying page 1 of 1.
    EudraCT Number: 2008-000885-21 Sponsor Protocol Number: BETA Start Date*: 2008-03-25
    Sponsor Name:TNO
    Full Title: The effect of betahistine 48 mg three times daily on motion sickness
    Medical condition: This study will evaluate the impact of betahistine on motion sickness.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027990 Motion sickness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002211-24 Sponsor Protocol Number: VITC-001 Start Date*: 2006-10-27
    Sponsor Name:FAZ - Floridsdorf Allergy Center
    Full Title: Wirksamkeit von oralem Vitamin C bei der Seekrankheit
    Medical condition: Die Seekrankheit (motion sickness) stellt ein weiterhin aktuelles Problem in der professionellen wie nicht-professionellen Seefahrt sowie auch beim Transport mit anderen Fortbewegungsmitteln (Auto,...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002180-24 Sponsor Protocol Number: 2004An0007 Start Date*: 2005-04-12
    Sponsor Name:Swindon & Marlborough NHS Trust
    Full Title: Prospective randomised double blind comparative study of cinnarizine versus placebo as prophylactic anti-travel sickness therapy in patients undergoing dy-case gynaecological surgery.
    Medical condition: Post operative nausea and vomiting and motion sickness
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000777-80 Sponsor Protocol Number: SENS111-202 Start Date*: 2018-06-08
    Sponsor Name:Sensorion
    Full Title: A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed...
    Medical condition: healthy volunteers (medicine for acute unilateral vertigo)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000298-23 Sponsor Protocol Number: PALO-04-07 Start Date*: 2005-07-19
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Randomized, Double-blind, Multicenter, Parallel Group, Balanced, Stratified Phase 3 Study to Evaluate the Efficacy and the Safety of Single IV Doses of Palonosetron 0.025 mg, 0.050 mg, and 0.075 ...
    Medical condition: Postoperative nausea and vomiting.
    Disease: Version SOC Term Classification Code Term Level
    10054133 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005216-28 Sponsor Protocol Number: VNK115640 Start Date*: 2012-04-05
    Sponsor Name:GlaxoSmithKline
    Full Title: A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 3...
    Medical condition: Post-operative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022117 - Injury, poisoning and procedural complications 10036285 Postoperative nausea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003992-30 Sponsor Protocol Number: DP10019 Start Date*: 2016-03-08
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had prior prophylaxis
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007770-37 Sponsor Protocol Number: DP10002 Start Date*: 2009-05-29
    Sponsor Name:Acacia Pharma Ltd.
    Full Title: Randomised, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of different doses of intravenous APD405 (buspirone for IV injection) for the prevention of post-opera...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-001021-22 Sponsor Protocol Number: NKO101287 Start Date*: 2005-02-08
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-004267-71 Sponsor Protocol Number: DP10006 Start Date*: 2011-12-12
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomiting
    Medical condition: Post-operative nausea and vomiting (PONV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002041-59 Sponsor Protocol Number: DP10018 Start Date*: 2015-09-11
    Sponsor Name:Acacia Pharma Ltd
    Full Title: Randomised, double-blind, placebo-controlled study of APD421 (amisulpride for IV injection) as treatment of established post-operative nausea and vomiting, in patients who have had no prior prophyl...
    Medical condition: Post-operative nausea and vomiting
    Disease: Version SOC Term Classification Code Term Level
    18.1 10022117 - Injury, poisoning and procedural complications 10066962 Procedural nausea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005856-42 Sponsor Protocol Number: NKT102553 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Preventi...
    Medical condition: Postoperative Nausea and Vomiting (PONV)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000369-37 Sponsor Protocol Number: NKT102245 Start Date*: 2005-02-01
    Sponsor Name:GlaxoSmithKline Group of Companies
    Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun...
    Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005855-16 Sponsor Protocol Number: NKT102552 Start Date*: 2006-03-20
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for...
    Medical condition: Postoperative Nausea and Vomiting (PONV)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) HU (Completed) ES (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014582-51 Sponsor Protocol Number: MO-90020714 Start Date*: 2010-03-26
    Sponsor Name:Faculty of Medicine, Technische Universität München
    Full Title: Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels
    Medical condition: Patients with severe Atopic dermatitis and total IgE-level > 700 IU/ml (potentially associated with bronchial asthma and/or allergic rhinitis)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002198 Anaphylactic reaction LLT
    12.0 10040400 Serum sickness LLT
    12.0 10043554 Thrombocytopenia LLT
    12.0 10019211 Headache LLT
    12.0 10028810 Nasopharyngitis LLT
    12.0 10040753 Sinusitis LLT
    12.0 10022000 Influenza LLT
    12.0 10006451 Bronchitis LLT
    12.0 10017888 Gastroenteritis LLT
    12.0 10034835 Pharyngitis LLT
    12.0 10047461 Viral infection LLT
    12.0 10034844 Pharyngolaryngeal pain LLT
    12.0 10011224 Cough LLT
    12.0 10039083 Rhinitis LLT
    12.0 10028735 Nasal congestion LLT
    12.0 10039085 Rhinitis allergic LLT
    12.0 10012727 Diarrhea LLT
    12.0 10028813 Nausea LLT
    12.0 10013946 Dyspepsia LLT
    12.0 10003988 Back pain LLT
    12.0 10003239 Arthralgia LLT
    12.0 10028411 Myalgia LLT
    12.0 10033425 Pain in extremity LLT
    12.0 10041014 Sleepiness LLT
    12.0 10046735 Urticaria LLT
    12.0 10015587 Exanthema LLT
    12.0 10037087 Pruritus LLT
    12.0 10012485 Dermatitis photosensitive LLT
    12.0 10000357 Accelerated hair loss LLT
    12.0 10033775 Paraesthesia LLT
    12.0 10042772 Syncope LLT
    12.0 10064973 Allergic bronchospasm LLT
    12.0 10001736 Allergic vasculitis LLT
    12.0 10053354 Blood pressure orthostatic abnormal LLT
    12.0 10063927 Orthostatic intolerance LLT
    12.0 10000188 Abnormal weight gain LLT
    12.0 10030095 Oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001275-21 Sponsor Protocol Number: TAK-906-2002 Start Date*: 2019-06-18
    Sponsor Name:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine ...
    Medical condition: Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10018043 Gastroparesis LLT
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    20.1 10017947 - Gastrointestinal disorders 10021227 Idiopathic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA